pirogovestnikВестник Национального медико-хирургического центра им. Н.И. ПироговаBulletin of Pirogov National Medical & Surgical Center2072-82552782-3628Национальный медико-хирургический Центр им. Н.И. Пирогова10.25881/20728255_2024_19_4_S1_119pirogovestnik-211Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESАНТИ-VEGF ПРЕПАРАТЫ ПРИ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИANTI-VEGF THERAPY FOR DIABETIC RETINOPATHYЧехонинЕ. С.ChekhoninE. S.

Москва 

Moscow

dr.chekhonin@gmail.comПавловскийО. А.PavlovskiyO. A.

Москва

Moscow

ФГБУ Национальный медико-хирургический Центр им. Н.И. ПироговаРоссияPirogov National Medical and Surgical CenterRussian FederationФГБУ Национальный медико-хирургический Центр им. Н.И. Пирогова; Институт усовершенствования врачей, Национальный медико-хирургический Центр им. Н.И. ПироговаРоссияPirogov National Medical and Surgical Center; Institute of Advanced Training of PhysiciansRussian Federation202413112024194приложение 1119123Copyright © Чехонин Е.С., Павловский О.А., 20242024Чехонин Е.С., Павловский О.А.Chekhonin E.S., Pavlovskiy O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://submit.pirogov-vestnik.ru/jour/article/view/211

Диабетическая ретинопатия – одно из наиболее тяжёлых осложнений сахарного диабета, требующее участия врачей разных специальностей: эндокринологов, диабетологов, терапевтов, кардиологов, хирургов, анестезиологов и других.

Задача офтальмолога – выявить патологические изменения в глазу, связанные с сахарным диабетом, и назначить соответствующее лечение.

Есть три основных метода лечения диабетической ретинопатии: 

В данном обзоре литературы рассматривается применение ингибиторов эндотелиального фактора роста сосудов при лечении диабетической ретинопатии. В частности, обсуждаются наиболее актуальные лекарственные препараты, важнейшие исследования по терапии ДР и диабетического макулярного отёка, а также post hoc анализ этих исследований. Также обсуждается роль этих препаратов в терапии рефрактерного ДМО. Также затрагиваются будущие стратегии терапии и значение лекарственных препаратов для профилактики развития ДР и ДМО.

Diabetic retinopathy is one of the most severe complications of diabetes mellitus, requiring the participation of doctors of various specialties: endocrinologists, diabetologists, therapists, cardiologists, surgeons, anesthesiologists and others.

The task of an ophthalmologist is to identify pathological changes in the eye associated with diabetes mellitus and prescribe appropriate treatment.

There are three main methods for treating diabetic retinopathy: 

This literature review examines the use of vascular endothelial growth factor inhibitors in the treatment of diabetic retinopathy. In particular, it discusses the most relevant drugs, the most important studies on the therapy of DR and diabetic macular edema, as well as a post hoc analysis of these studies. In addition, the role of these drugs in the therapy of refractory DME is discussed.

Анти-VEGFдиабетический макулярный отекдиабетическая ретинопатияAnti-VEGFdiabetic macular edemadiabetic rethinopathyReferencesРоль блокады ангиогенеза у пациентов с диабетической ретинопатией / Е. С. Чехонин, Р. Р. Файзрахманов, М. М. Шишкин, М. Р. Каланов // Офтальмохирургия. – 2022. – № 4. – С. 85-91. – DOI 10.25276/0235-4160-2022-4-85-91. – EDN CUIZPC.Chekhonin E.S., Fayzrakhmanov R.R., Shishkin M.M., Kalanov M.R. Role of inhibition of angiogenesis in patients with diabetic retinopathy. Fyodorov Journal of Ophthalmic Surgery. 2022;4: 85–91. doi: 10.25276/0235-4160-2022-4-85-91 (In Russ.)Анти-VEGF препараты в лечении диабетической ретинопатии / Е. С. Чехонин, Р. Р. Файзрахманов, А. В. Суханова, Э. Д. Босов // Вестник офтальмологии. – 2021. – Т. 137, № 4. – С. 136-142. – DOI 10.17116/ oftalma2021137041136. – EDN YJDKIK.Chekhonin ES, Fayzrakhmanov RR, Sukhanova AV, Bosov ED. Anti-VEGF therapy for diabetic retinopathy. Russian Annals of Ophthalmology. 2021;137(4):136 142. (In Russ.)Чехонин, Е. С. Анти-VEGF при диабетической ретинопатии: новые перспективы / Е. С. Чехонин // Вестник Национального медико-хирургического центра им. Н.И. Пирогова. – 2022. – Т. 17, № S4. – С. 54-56. – DOI 10.25881/20728255_2022_17_4_S1_54. – EDN IRTPQM.Chekhonin E.S. Anti-VEGF for diabetic retinopathy: new perspectives. Bulletin of Pirogov National Medical & Surgical Center. 2022;17(4,supplement):54-56. (In Russ.)Современное представление о неоваскулярной глаукоме (обзор) / Р. Р. Файзрахманов, М. Е. Калинин, О. А. Павловский [и др.] // Офтальмологические ведомости. – 2023. – Т. 16, № 3. – С. 99-108. – DOI 10.17816/OV490823. – EDN EOIVPW.Fayzrakhmanov R.R., Kalinin M.E., Pavlovsky O.A., Chekhonin E.S., Sekhina O.L. Modern concept of neovascular glaucoma (review) // Ophthalmology Reports. – 2023. – Vol. 16. – N. 3. – P. 99-108. (In Russ.)Изменение толщины центральной зоны сетчатки после витрэктомии по поводу регматогенной отслойки сетчатки с использованием силиконовой тампонады / Р. Р. Файзрахманов, А. В. Суханова, О. А. Павловский [и др.] // Вестник Национального медико-хирургического центра им. Н.И. Пирогова. – 2020. – Т. 15, № 2. – С. 89-91. – DOI 10.25881/BPNMSC.2020.32.27.015. – EDN IVIYJZ.The change in the thickness of the central zone of the retina after vitrectomy due to rhegmatogenous detachment of the retina using silicone tamponade / R. R. Faizrakhmanov, A. V. Sukhanova, O. A. Pavlovskii [i dr.] // Vestnik Natsional’nogo mediko-khirurgicheskogo tsentra im. N.I. Pirogova. – 2020. – T. 15, № 2. – S. 89-91. – DOI 10.25881/BPNMSC.2020.32.27.015. – EDN IVIYJZ. (In Russ.)Uehara F, Ohba N, Ozawa M. Isolation and characterization of galectins in the mammalian retina. Invest Ophthalmol Vis Sci. 2001;42(10):2164-2172.Uehara F, Ohba N, Ozawa M. Isolation and characterization of galectins in the mammalian retina. Invest Ophthalmol Vis Sci. 2001;42(10):2164-2172.Kanda A, Noda K, Saito W, et al. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep. 2015;5:17946. https://doi.org/10.1038/srep17946Kanda A, Noda K, Saito W, et al. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep. 2015;5:17946. https://doi.org/10.1038/srep17946Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M, Rabinovich GA. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014;156(4):744-758. https://doi.org/10.1016/j.cell.2014.01.043Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M, Rabinovich GA. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014;156(4):744-758. https:// doi.org/10.1016/j.cell.2014.01.043Yule Xu, Ao Rong, Yanlong Bi, Wei Xu. Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice. J Ophthalmol. 2016; 2016:2143082. https://doi.org/10.1155/2016/2143082Yule Xu, Ao Rong, Yanlong Bi, Wei Xu. Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice. J Ophthalmol. 2016; 2016:2143082. https://doi.org/10.1155/2016/2143082Tadayoni R, Sararols L, Weissgerber G. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93-101. https://doi.org/10.1159/000513048Tadayoni R, Sararols L, Weissgerber G. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93-101. https://doi.org/10.1159/000513048Corradetti G, Corvi F, Nguyen TV, Sadda SR. Management of Neovascular Age-Related Macular Degeneration during the COVID-19 Pandemic. Ophthalmol Retina. 2020;4(8):757-759. https://doi.org/10.1016/j.ophtha.2019.12.031Corradetti G, Corvi F, Nguyen TV, Sadda SR. Management of Neovascular Age-Related Macular Degeneration during the COVID-19 Pandemic. Ophthalmol Retina. 2020;4(8):757-759. https://doi.org/10.1016/j.ophtha.2019.12.031Dugel PU. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89-99. https://doi.org/10.1016/j.ophtha.2020.06.028Dugel PU. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89-99. https://doi.org/10.1016/j.ophtha.2020.06.028Brown D, Wolf S, Garweg JG, et al. Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KESTREL & KITE studies, May 1—7, 2021, ARVO, Poster.Brown D, Wolf S, Garweg JG, et al. Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KESTREL & KITE studies, May 1—7, 2021, ARVO, Poster.Heier, J.S.; Khanani, A.M.; Quezada Ruiz, C.; Basu, K.; Ferrone, P.J.; Brittain, C.; Figueroa, M.S.; Lin, H.; Holz, F.G.; Patel, V.; et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular agerelated macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022, 399, 729–740.Heier, J.S.; Khanani, A.M.; Quezada Ruiz, C.; Basu, K.; Ferrone, P.J.; Brittain, C.; Figueroa, M.S.; Lin, H.; Holz, F.G.; Patel, V.; et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular agerelated macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022, 399, 729–740.Wykoff, C.C.; Abreu, F.; Adamis, A.P.; Basu, K.; Eichenbaum, D.A.; Haskova, Z.; Lin, H.; Loewenstein, A.; Mohan, S.; Pearce, I.A.; et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials. Lancet 2022, 399, 741–755.Wykoff, C.C.; Abreu, F.; Adamis, A.P.; Basu, K.; Eichenbaum, D.A.; Haskova, Z.; Lin, H.; Loewenstein, A.; Mohan, S.; Pearce, I.A.; et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials. Lancet 2022, 399, 741–755.Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, Scott LC. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol. 2017;11:393-401. https://doi.org/10.2147/OPTH.S128509Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, Scott LC. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol. 2017;11:393-401. https://doi.org/10.2147/OPTH.S128509Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351-1359. https://doi.org/10.1016/j.ophtha.2016.02.022Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351-1359. https://doi.org/10.1016/j.ophtha.2016.02.022Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK; DRCR Retina Network. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA. 2019;321(19): 1880-1894. https://doi.org/10.1001/jama.2019.5790Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK; DRCR Retina Network. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA. 2019;321(19): 1880-1894. https://doi.org/10.1001/jama.2019.5790Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and longterm outcome in diabetic macular edema: an independent analysis of protocol I study data. Retina. 2019;39(1):88-97. https://doi.org/10.1097/IAE.0000000000002110Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and longterm outcome in diabetic macular edema: an independent analysis of protocol I study data. Retina. 2019;39(1):88-97. https://doi.org/10.1097/IAE.0000000000002110Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA; Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017;135(6):558-568. https://doi.org/10.1001/jamaophthalmol.2017.0821Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA; Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017;135(6):558-568. https://doi.org/10.1001/jamaophthalmol.2017.0821Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145-1152. https://doi.org/10.1001/archophthalmol.2012.1043Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145-1152. https://doi.org/10.1001/archophthalmol.2012.1043Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015;122(2):367-374. https://doi.org/10.1016/j.ophtha.2014.08.048Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015;122(2):367-374. https://doi.org/10.1016/j.ophtha.2014.08.048Wykoff CC. Intravitreal aflibercept for moderately severe to severe nonproliferative diabetic retinopathy (NPDR): the Phase III PANORAMA Study. American Society of Retina Specialists Annual Meeting; 2018, Vancouver, Canada.Wykoff CC. Intravitreal aflibercept for moderately severe to severe nonproliferative diabetic retinopathy (NPDR): the Phase III PANORAMA Study. American Society of Retina Specialists Annual Meeting; 2018, Vancouver, Canada.Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376-2385. https://doi.org/10.1016/j.ophtha.2016.07.032Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376-2385. https://doi.org/10.1016/j.ophtha.2016.07.032Sugimoto M, Ichio A, Mochida D, et al. Multiple effects of intravitreal aflibercept on microvascular regression in eyes with diabetic macular edema. Ophthalmol Retina. 2019;3:1067-1075. https://doi.org/10.1016/j.oret.20-19.06.005Sugimoto M, Ichio A, Mochida D, et al. Multiple effects of intravitreal aflibercept on microvascular regression in eyes with diabetic macular edema. Ophthalmol Retina. 2019;3:1067-1075. https://doi.org/10.1016/j.oret.20-19.06.005Wykoff CC, Shah C, Dhoot D, et al. Longitudinal retinal perfusion status in eyes with diabetic macular edema receiving intravitreal aflibercept or laser in VISTA study. Ophthalmology. 2019;126(8):1171-1180. https://doi.org/10.1016/j.ophtha.2019.03.040Wykoff CC, Shah C, Dhoot D, et al. Longitudinal retinal perfusion status in eyes with diabetic macular edema receiving intravitreal aflibercept or laser in VISTA study. Ophthalmology. 2019;126(8):1171-1180. https://doi.org/10.1016/j.ophtha.2019.03.040MJ E. To treat or not to treat: are we sacrificing treatment outcomes by allowing diabetic retinopathy (DR) to enter the proliferative stage? American Society of Retina Specialists Annual Meeting; 2018, Vancouver, Canada.MJ E. To treat or not to treat: are we sacrificing treatment outcomes by allowing diabetic retinopathy (DR) to enter the proliferative stage? American Society of Retina Specialists Annual Meeting; 2018, Vancouver, Canada.Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol. 2017;28(6):636-643. https://doi.org/10.1097/ICU.0000000000000424Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol. 2017;28(6):636-643. https://doi.org/10.1097/ICU.0000000000000424Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Costeffectiveness of treatment of diabetic macular edema. Ann Intern Med. 2014;160(1):18-29. https://doi.org/10.7326/M13-0768Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Costeffectiveness of treatment of diabetic macular edema. Ann Intern Med. 2014;160(1):18-29. https://doi.org/10.7326/M13-0768Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular-thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for center-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3): 257-269. https://doi.org/10.1001/jamaophthalmol.2017.6565Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular-thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for center-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3): 257-269. https://doi.org/10.1001/jamaophthalmol.2017.6565Dugel PU, Layton A, Varma RB. Diabetic macular edema diagnosis and treatment in the real world: an analysis of medicare claims data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):258-267. https://doi.org/10.3928/23258160-20160229-09Dugel PU, Layton A, Varma RB. Diabetic macular edema diagnosis and treatment in the real world: an analysis of medicare claims data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):258-267. https://doi.org/10.3928/23258160-20160229-09Bolinger MT, Antonetti DA. Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. Int J Mol Sci. 2016;17(9):1498. https://doi.org/10.3390/ijms17091498Bolinger MT, Antonetti DA. Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. Int J Mol Sci. 2016;17(9):1498. https://doi.org/10.3390/ijms17091498Spencer DB, Protopsaltis NJ, Chao DL. New pharmacotherapies for diabetic retinopathy. Ann Eye Sci. 2018;3(43):1-13. https://doi.org/10.21037/aes.2018.08.02Spencer DB, Protopsaltis NJ, Chao DL. New pharmacotherapies for diabetic retinopathy. Ann Eye Sci. 2018;3(43):1-13. https://doi.org/10.21037/aes.2018.08.02Stewart MW. Future treatments of diabetic retinopathy: pharmacotherapeutic products under development. Eur Med J Diabetes. 2017;5(1):93-103.Stewart MW. Future treatments of diabetic retinopathy: pharmacotherapeutic products under development. Eur Med J Diabetes. 2017;5(1):93-103.Bahrami B, Zhu M, Hong T, Chang A. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia. 2016;59(8):1594-1608. https://doi.org/10.1007/s00125-016-3974-8Bahrami B, Zhu M, Hong T, Chang A. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia. 2016;59(8):1594-1608. https://doi.org/10.1007/s00125-016-3974-8Dhoot DS, Pieramici DJ, Nasir M, Castellarin AA, Couvillion S, See RF, Steinle N, Bennett M, Rabena M, Avery RL. Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond). 2015;29(4):534-541. https://doi.org/10.1038/eye.2014.338Dhoot DS, Pieramici DJ, Nasir M, Castellarin AA, Couvillion S, See RF, Steinle N, Bennett M, Rabena M, Avery RL. Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond). 2015;29(4):534-541. https://doi.org/10.1038/eye.2014.338Ciulla TA, Hussain RM, Ciulla LM, Sink B, Harris A. Ranibizumab for diabetic macular edema refractory to multiple prior treatments. Retina. 2016; 36(7):1292-1297. https://doi.org/10.1097/IAE.0000000000000876Ciulla TA, Hussain RM, Ciulla LM, Sink B, Harris A. Ranibizumab for diabetic macular edema refractory to multiple prior treatments. Retina. 2016; 36(7):1292-1297. https://doi.org/10.1097/IAE.0000000000000876Hanhart J, Chowers I. Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. Case Rep Ophthalmol. 2015;6(1):44-50. https://doi.org/10.11-59/000375230Hanhart J, Chowers I. Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. Case Rep Ophthalmol. 2015;6(1):44-50. https://doi.org/10.11-59/000375230Ashraf M, Souka AA, ElKayal H. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases with Non-Response to Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017; 48(3):230-236. https://doi.org/10.3928/23258160-20170301-06Ashraf M, Souka AA, ElKayal H. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases with NonResponse to Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017; 48(3):230-236. https://doi.org/10.3928/23258160-20170301-06

The authors declare that there are no conflicts of interest present.